drugset
Drugs / GSK3174998
last change Apr 2025 re-read 9 days ago

GSK3174998

Monoclonal antibody targets TNFRSF4 via activation

Developed for
neoplasm · plasma cell myeloma · refractory plasma cell neoplasm
Investigated by
GlaxoSmithKline · Merck Sharp & Dohme LLC · IQVIA Pty Ltd

Trials 5

today NCT06160609 · Ph 1/2 NCT04126200 · Ph 1/2 NCT03447314 · Ph 1 NCT02723955 · Ph 1 NCT02528357 · Ph 1
201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 13 trials
Phase 1 NCT03447314 Mar 2018 → Jul 2020 neoplasm GlaxoSmithKline Completed No outcome recorded
Phase 1 NCT02723955 Jun 2016 → Jul 2023 neoplasm GlaxoSmithKline Completed No outcome recorded
Phase 1 NCT02528357 Sep 2015 → Apr 2020 neoplasm GlaxoSmithKline Completed No outcome recorded
Phase 1/22 trials
Phase 1/2 NCT06160609 Oct 2019 → Jan 2023 refractory plasma cell neoplasm GlaxoSmithKline Terminated No outcome recorded
Phase 1/2 NCT04126200 Oct 2019 → Apr 2025 overdue plasma cell myeloma GlaxoSmithKline Active not recruiting No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

FieldValueCited text
Known as GSK3174998 ClinicalTrials.gov intervention name — accepted as the source's own label NCT02528357 ↗
4

NCT03447314 ↗

NCT04126200 ↗

NCT06160609 ↗

NCT02723955 ↗
Action Activate “Tumor necrosis factor receptor superfamily member 4 agonist” CHEMBL4297968 ↗
1

“OX40 agonist” PMID 36927527 ↗ Mar 2023
Modality Monoclonal antibody “the humanized IgG1 OX40 agonistic monoclonal antibody GSK3174998” PMID 36927527 ↗ Mar 2023
Route Intravenous “to be given as IV infusion for 30 minutes (min), Q3W” NCT02528357 ↗
Target TNFRSF4 “Tumor necrosis factor receptor superfamily member 4 agonist” CHEMBL4297968 ↗